InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Enliven Therapeutics, Inc.

ELVN Clue Score23
United States Fiscal year ends December CIK 0001672619 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

80
Insider
Date
Role
Action
Shares
Price
Amount
Lori Anne Kunkel
30 Oct 2026
Director
Exercised, kept
7,300
$18.30
$133.59K
Lori Anne Kunkel
30 Oct 2026
Director
Exercised, kept
3,741
$1.12
$4.19K
Helen Louise Collins
19 Oct 2026
Chief Medical Officer
Sold after exercise
5,000
$38.47
$192.34K
Benjamin Hohl
19 Oct 2026
Chief Financial Officer
Sold after exercise
6,018
$38.48
$231.55K
J. Scott Garland
1 Oct 2026
Director
Sold after exercise
13,000
$46.67
$606.72K
Helen Louise Collins
17 Sep 2026
Chief Medical Officer
Sold after exercise
240
$51.48
$12.36K
Helen Louise Collins
17 Sep 2026
Chief Medical Officer
Sold after exercise
1,844
$50.71
$93.51K
Helen Louise Collins
17 Sep 2026
Chief Medical Officer
Sold after exercise
2,916
$50.03
$145.89K
Benjamin Hohl
17 Sep 2026
Chief Financial Officer
Sold after exercise
289
$51.49
$14.88K
Benjamin Hohl
17 Sep 2026
Chief Financial Officer
Sold after exercise
2,194
$50.72
$111.27K
Benjamin Hohl
17 Sep 2026
Chief Financial Officer
Sold after exercise
3,535
$50.03
$176.85K
Helen Louise Collins
17 Aug 2026
Chief Medical Officer
Sold after exercise
1,100
$59.35
$65.28K
Helen Louise Collins
17 Aug 2026
Chief Medical Officer
Sold after exercise
3,900
$58.37
$227.65K
Benjamin Hohl
17 Aug 2026
Chief Financial Officer
Sold on a plan
1,388
$59.35
$82.38K
Benjamin Hohl
17 Aug 2026
Chief Financial Officer
Sold on a plan
4,630
$58.35
$270.17K
Mika K Derynck
4 Aug 2026
Director
Sold after exercise
158,795
$60.21
$9.56M
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
63
$53.92
$3.40K
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
2,184
$53.42
$116.67K
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
2,063
$52.39
$108.08K
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
459
$51.55
$23.66K
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
231
$50.05
$11.56K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
123
$53.87
$6.63K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
2,638
$53.38
$140.82K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
2,564
$52.32
$134.14K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
369
$51.48
$19.00K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
324
$49.97
$16.19K
Lori Anne Kunkel
6 Jul 2026
Director
Sold on a plan
5,889
$50.84
$299.42K
Lori Anne Kunkel
6 Jul 2026
Director
Sold on a plan
4,111
$49.98
$205.48K
Orbimed Advisors LLC
22 Jun 2026
10% owner
Sell indirect
46,776
$45.00
$2.10M
Orbimed Advisors LLC
22 Jun 2026
10% owner
Sell indirect
787,024
$45.38
$35.72M
Orbimed Advisors LLC
22 Jun 2026
10% owner
Sell indirect
1,477
$45.00
$66.47K
Orbimed Advisors LLC
22 Jun 2026
10% owner
Sell indirect
24,846
$45.38
$1.13M
Helen Louise Collins
17 Jun 2026
Chief Medical Officer
Sold after exercise
1,133
$44.74
$50.69K
Helen Louise Collins
17 Jun 2026
Chief Medical Officer
Sold after exercise
2,599
$43.87
$114.02K
Helen Louise Collins
17 Jun 2026
Chief Medical Officer
Sold after exercise
1,268
$42.83
$54.30K
Benjamin Hohl
17 Jun 2026
Chief Financial Officer
Sold after exercise
1,238
$44.75
$55.40K
Benjamin Hohl
17 Jun 2026
Chief Financial Officer
Sold after exercise
3,401
$43.86
$149.18K
Benjamin Hohl
17 Jun 2026
Chief Financial Officer
Sold after exercise
1,379
$42.79
$59.00K
Orbimed Advisors LLC
15 Jun 2026
10% owner
Sell indirect
272,322
$45.02
$12.26M
Orbimed Advisors LLC
15 Jun 2026
10% owner
Sell indirect
9,086
$45.02
$409.05K
Lori Anne Kunkel
5 Jun 2026
Director
Sold on a plan
354
$35.82
$12.68K
Lori Anne Kunkel
5 Jun 2026
Director
Sold on a plan
1,867
$35.36
$66.01K
Lori Anne Kunkel
5 Jun 2026
Director
Sold on a plan
7,779
$34.28
$266.66K
Helen Louise Collins
18 May 2026
Chief Medical Officer
Sold after exercise
223
$41.21
$9.19K
Helen Louise Collins
18 May 2026
Chief Medical Officer
Sold after exercise
1,302
$40.25
$52.40K
Helen Louise Collins
18 May 2026
Chief Medical Officer
Sold after exercise
3,475
$39.53
$137.38K
Helen Louise Collins
17 Apr 2026
Chief Medical Officer
Sold after exercise
2,441
$48.06
$117.30K
Helen Louise Collins
17 Apr 2026
Chief Medical Officer
Sold after exercise
2,419
$47.39
$114.64K
Helen Louise Collins
17 Apr 2026
Chief Medical Officer
Sold after exercise
140
$45.81
$6.41K
Helen Louise Collins
25 Mar 2026
Chief Medical Officer
Sold after exercise
40,000
$35.10
$1.40M
Helen Louise Collins
17 Mar 2026
Chief Medical Officer
Sold after exercise
5,000
$27.76
$138.80K
Helen Louise Collins
10 Mar 2026
Chief Medical Officer
Sold after exercise
10,129
$30.19
$305.83K
Helen Louise Collins
9 Mar 2026
Chief Medical Officer
Sold after exercise
29,871
$30.02
$896.81K
Benjamin Hohl
6 Mar 2026
Chief Financial Officer
Sell
10,000
$29.58
$295.84K
Helen Louise Collins
17 Feb 2026
Chief Medical Officer
Sold after exercise
45,000
$26.17
$1.18M
Richard A. Heyman
17 Feb 2026
Director
Sold on a plan indirect
1,230
$26.18
$32.20K
Joseph P Lyssikatos
6 Feb 2026
Chief Scientific Officer
Sold on a plan indirect
5,000
$29.04
$145.22K
Richard A. Heyman
20 Jan 2026
Director
Sold on a plan indirect
718
$26.96
$19.35K
Richard A. Heyman
20 Jan 2026
Director
Sold on a plan indirect
512
$26.46
$13.55K
Joseph P Lyssikatos
20 Jan 2026
Chief Scientific Officer
Sold on a plan indirect
14,509
$26.90
$390.28K
Joseph P Lyssikatos
20 Jan 2026
Chief Scientific Officer
Sold on a plan indirect
5,491
$26.37
$144.81K
Richard A. Heyman
9 Jan 2026
Director
Sold on a plan indirect
4,285
$25.00
$107.13K
Joseph P Lyssikatos
9 Jan 2026
Chief Scientific Officer
Sold on a plan indirect
50,000
$29.13
$1.46M
Joseph P Lyssikatos
9 Jan 2026
Chief Scientific Officer
Sold on a plan indirect
41,198
$24.90
$1.03M
Anish Patel
9 Jan 2026
Chief Operating Officer
Sold on a plan indirect
243
$28.50
$6.93K
Anish Patel
9 Jan 2026
Chief Operating Officer
Sold on a plan indirect
48,057
$27.98
$1.34M
Richard A. Heyman
8 Jan 2026
Director
Sold on a plan indirect
8,015
$25.04
$200.66K
Richard A. Heyman
8 Jan 2026
Director
Sold on a plan indirect
1,620
$25.00
$40.50K
Joseph P Lyssikatos
8 Jan 2026
Chief Scientific Officer
Sold on a plan indirect
33,802
$24.92
$842.47K
Joseph P Lyssikatos
8 Jan 2026
Chief Scientific Officer
Sold on a plan indirect
7,500
$20.13
$150.96K
Benjamin Hohl
22 Dec 2025
Chief Financial Officer
Exercised, kept
13,000
$2.48
$32.24K
Joseph P Lyssikatos
19 Dec 2025
Chief Scientific Officer
Sold on a plan indirect
5,000
$16.84
$84.21K
Lori Anne Kunkel
17 Dec 2025
Director
Exercised, kept
15,958
$1.12
$17.87K
Anish Patel
8 Dec 2025
Chief Operating Officer
Sold on a plan indirect
1,705
$21.78
$37.13K
Anish Patel
8 Dec 2025
Chief Operating Officer
Sold on a plan indirect
4,958
$20.76
$102.94K
Joseph P Lyssikatos
19 Nov 2025
Chief Scientific Officer
Sold on a plan indirect
492
$23.09
$11.36K
Joseph P Lyssikatos
19 Nov 2025
Chief Scientific Officer
Sold on a plan indirect
12,008
$22.30
$267.79K
Samuel Kintz
17 Nov 2025
President and CEO
Sold on a plan indirect
12,500
$21.82
$272.74K
Anish Patel
7 Nov 2025
Chief Operating Officer
Sold on a plan indirect
613
$17.94
$11.00K
Anish Patel
7 Nov 2025
Chief Operating Officer
Sold on a plan indirect
6,054
$17.35
$105.04K

What was left out

Form 4 filings counted 52
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 30
Sales straight out of an exercise 39
Sales at will 7
Transactions with no price 0
Shares from compensation/vesting 482,634
History held since 16 Mar 2020